Clinical Research Details
Title:
A Phase III, Randomized, Double Blind Study of Galiximab in Combination with Rituximab compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma.
Purpose:
The primary purpose is to compare the clinical benefit of galiximab in combination with rituximab with that of rituximab monotherapy for relapsed or refractory follicular non-Hodgkin's lymphoma.
Study Number:
109247
Number of Patients:
700
Elgibility:
Adults (> 18) with confirmed non-Hodgkin's lymphoma, relapsed or progressive disease after at least 1 prior chemotherapy treatment.
Treatment:
You will receive an intravenous infusion of rituximab in combination with galiximab or a placebo once weekly for four weeks.
Principal Investigator:
Enrollment Phone:
(708) 327-3223